Skip to content

Total debt at other companies

Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$80.49M-32.5%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$787.64M+259%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$250.82M+58.6%
Regenxbio logo
RegenxbioRGNX
$71.07M-11.0%
Eli Lilly logo
Eli LillyLLY
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $114.51M.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's total debt?
Prime Medicine (PRME) reported total debt of $114.51M in Q1 2026.
How has Prime Medicine's total debt changed year-over-year?
Prime Medicine's total debt decreased by 5.5% year-over-year, from $121.15M to $114.51M.
What is the long-term trend for Prime Medicine's total debt?
Over 5 years (2020 to 2025), Prime Medicine's total debt has grown at a 112.3% compound annual growth rate (CAGR), from $2.7M to $116.43M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.